Related Experiment Video

Updated: Nov 25, 2025

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

7.1K

Anti-viral immunity in the tumor microenvironment: implications for the rational design of herpes simplex virus type

Paul J F Rider1, Ifeanyi K Uche1, Larissa Sweeny1,2

  • 1Division of Biotechnology and Molecular Medicine and Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, USA.

Current Clinical Microbiology Reports
|December 21, 2020
PubMed
Abstract

Insights

Designing novel herpes simplex type I (HSV-1) oncolytic virotherapies involves balancing safety, immunogenicity, and replication. Enhancing HSV-1's ability to overcome tumor microenvironment defenses improves efficacy.

Area of Science:

  • Oncolytic virotherapy
  • Herpes simplex virus type 1 (HSV-1) research
  • Tumor microenvironment immunology

Background:

  • Designing effective oncolytic virotherapies requires balancing safety, immunogenicity, and viral replication potential.
  • Herpes simplex virus type 1 (HSV-1) is a common platform for developing oncolytic viruses.

Purpose of the Study:

  • To review rational approaches for designing novel herpesvirus oncolytic virotherapies.
  • To understand how safety, immunogenicity, and replicative potential are incorporated into HSV-1 derived therapies.

Main Methods:

  • Review of recent scientific literature on HSV-1 oncolytic virotherapy.
  • Analysis of studies investigating viral mechanisms within the tumor microenvironment.

Main Results:

  • Enhanced HSV-1 oncolytic viruses demonstrate greater efficacy by combating anti-viral mechanisms in the tumor microenvironment.
  • Manipulation of tumor microenvironment immunosuppression enhances oncolytic virotherapy efficacy.

Conclusions:

  • The impact of the immunosuppressive tumor microenvironment on oncolytic viral replication and spread requires further elucidation.
  • Future research will integrate a deeper understanding of tumor immunosuppression into the design of oncolytic virotherapies.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.8K
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

9.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
880
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.1K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.3K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
1.3K